Key Points Pfizer's stock has declined 40% over the past three years, as it has struggled to attract investors. Investors appear to be underrating its growth prospects, as the company has a robust pipeline. Its low valuation and high yield could make the stock too attractive to pass up. 10 stocks we like better than Pfizer › Shares of pharmaceutical giant Pfizer (NYSE: PFE) have been crashing for ...
Key Points Pfizer's stock has declined 40% over the past three years, as it has struggled to attract investors. Investors appear to be underrating its growth prospects, as the company has a robust pipeline. Its low valuation and high yield could make the stock too attractive to pass up. 10 stocks we like better than Pfizer › Shares of pharmaceutical giant Pfizer (NYSE: PFE) have been crashing for multiple years. The last time it posted a positive gain was in 2021, when it rose by more than 60%. Back then, business was booming as demand for its COVID products was strong. Today, however, the company is struggling to generate much growth. Investors are also concerned about what's ahead for the business and whether things will get much better for the company. The end result is not much excitement and bullishness around Pfizer's stock. But that could change in 2026, as there are multiple potential catalysts that could turn its fortunes around. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Pfizer says it is "rich in catalysts" Although there may be uncertainty ahead for Pfizer, management remains optimistic about the future, and it has been investing heavily in it. The pharmaceutical company has many potential drugs in development. As of Nov. 4, 2025, the company had 101 trials ongoing. And in a recent email to investors, Pfizer highlighted many potential milestones upcoming in research & development, stating that 2026 is a year "rich in catalysts" as the company expects to initiate over 20 pivotal Phase 3 trials. For Pfizer, approval or even encouraging results about a key drug could be the spark the business needs to win over growth-oriented investors and convince them that it's on the right track. And with so many late-stage trials ongoing, there's reason to be optimistic that its growth prospects will get an upgrade in the near future. The stock has been trading at a deep discount...
The Ministry of Finance. Photo: VCG China recorded its first annual decline in fiscal revenue since the Covid-19 pandemic, as a sharp fall in nontax takings outweighed a modest recovery in tax revenue. Data released by the Ministry of Finance showed general public budget (GPB) revenue fell 1.7% in 2025 from the previous year, marking the first contraction since 2020, when revenue slid during the i...
The Ministry of Finance. Photo: VCG China recorded its first annual decline in fiscal revenue since the Covid-19 pandemic, as a sharp fall in nontax takings outweighed a modest recovery in tax revenue. Data released by the Ministry of Finance showed general public budget (GPB) revenue fell 1.7% in 2025 from the previous year, marking the first contraction since 2020, when revenue slid during the initial pandemic shock. GPB is the largest of the four budgets in China’s fiscal system. The decline came despite a gradual improvement in economic activity over the year.
China will press ahead with building a unified market to unleash domestic consumption as countries around Asia face a “pivotal juncture” in the transformation of the global economy, a top economic official said. As the country opens its economy further, it will create more business opportunities for the region, Vice Finance Minister Liao Min said in a speech delivered on Wednesday at a meeting of ...
China will press ahead with building a unified market to unleash domestic consumption as countries around Asia face a “pivotal juncture” in the transformation of the global economy, a top economic official said. As the country opens its economy further, it will create more business opportunities for the region, Vice Finance Minister Liao Min said in a speech delivered on Wednesday at a meeting of finance and central bank deputies from Asia‑Pacific Economic Cooperation (APEC) member economies in Shanghai. “China is shifting towards new growth drivers in order to pursue high-quality development,” Liao said. “We are pressing ahead with building a unified market to further unleash domestic demand and consumption potential. Particularly services consumption is gaining strong momentum. The Chinese economy will be increasingly demand-driven.” The comments came as Chinese authorities have repeatedly vowed to dismantle local protectionism and inter-provincial trade barriers, which have suppressed consumption and fueled industrial overcapacity — sparking a prolonged price war and exacerbating trade tensions. China’s economic growth matched the government’s goal of 5% last year, with exports contributing a third of the expansion while domestic demand stayed subdued. The lopsided model is becoming increasingly unsustainable amid rising protectionism among trade partners, prompting Beijing to list boosting domestic demand as the top economic priority this year. Authorities have already taken some early measures to try to stimulate consumption and investment. They announced at the end of December initial public spending plans worth a total of $51 billion to invest in key national projects and provide subsidies for the consumer goods trade-in program. Last month, the People’s Bank of China delivered a 25-basis-point cut to the interest rates on its structural monetary policy tools and the Ministry of Finance unveiled a slew of loan perks to encourage businesses and consumers to bo...
Illegal Biolabs In Vegas & California Linked To Chinese National With Alleged Military-Civil Fusion Ties Authored by The Bureau's Sam Cooper , Federal and local authorities are investigating suspected illegal biological laboratories in Las Vegas and California’s Central Valley linked to a Chinese national accused by Congressional investigators of ties to a PRC military-civil fusion enterprise, who...
Illegal Biolabs In Vegas & California Linked To Chinese National With Alleged Military-Civil Fusion Ties Authored by The Bureau's Sam Cooper , Federal and local authorities are investigating suspected illegal biological laboratories in Las Vegas and California’s Central Valley linked to a Chinese national accused by Congressional investigators of ties to a PRC military-civil fusion enterprise, who spent a decade operating what Canadian courts found was a systematic technology-theft operation from British Columbia before fleeing south with a $330 million fraud judgment against him. The FBI and Las Vegas Metropolitan Police Department executed search warrants over the weekend at two residences connected to Jiabei “Jesse” Zhu, a 62-year-old Chinese citizen already under federal indictment for operating an illegal biolab in Reedley, California that contained labeled samples of at least 20 infectious agents including HIV, tuberculosis, and what the House Select Committee on the Chinese Communist Party described as “the deadliest known form of malaria.” Las Vegas Metro Sheriff Kevin McMahill confirmed Monday that investigators recovered over 1,000 samples of biological material “consistent in appearance” with items found in the California facility. “This can’t keep happening,” Congressman Kevin Kiley said after the Las Vegas raid, calling for immediate hearings on bipartisan legislation he introduced with Representatives Costa and David Valadao. “The illegal bio lab just raided in Las Vegas was operated by the same LLC and Chinese nationals as the one discovered in Reedley.” In the Reedley case, investigators discovered nearly 1,000 bioengineered laboratory mice, infectious agents including E. Coli, malaria, various chemicals, medical waste, blood, tissue, serum, body fluid samples, and illegal pregnancy tests, Congressman Jim Costa noted, citing the Select Committee’s review. Property records show both the Reedley warehouse and the Las Vegas homes are owned by the same l...
The software giant is being out-innovated by AI start-ups. Shares of Microsoft (MSFT +2.00%) crashed last week following the tech giant's latest earnings report. Investors were likely uneasy about a slowdown in cloud growth, a massive increase in AI infrastructure capital expenditures, and the revelation that nearly half of its backlog was tied to OpenAI. There was potentially another reason why i...
The software giant is being out-innovated by AI start-ups. Shares of Microsoft (MSFT +2.00%) crashed last week following the tech giant's latest earnings report. Investors were likely uneasy about a slowdown in cloud growth, a massive increase in AI infrastructure capital expenditures, and the revelation that nearly half of its backlog was tied to OpenAI. There was potentially another reason why investors turned on Microsoft: AI start-up Anthropic. Anthropic's Claude Code programming tool reached a $1 billion revenue run rate in just six months, and it's not hard to see why. Putting its powerful AI models in a loop to work through problems, with tooling that enables web search, file access, and more, turns out to be an incredibly effective way to write code. In January, Anthropic announced a research preview of a new product called Cowork. Microsoft should be very worried. "Why isn't Microsoft doing that?" Anthropic Cowork is essentially Claude Code, but for general computer tasks. It can organize files and folders, create spreadsheets, and even complete tasks in a browser. One example Anthropic gave was going through screenshots of receipts and producing a spreadsheet listing all expenses. Cowork opens the door to powerful and useful automations and workflows on the PC. It's almost incredible that Microsoft, which dominates the PC operating system market with Windows and the productivity software market with Office, doesn't offer anything like this. Analyst Ben Reitzes, speaking to CNBC, summed up the problem: "It is a little embarrassing that in 10 days, Anthropic was able to invent, co-work, put it out and everybody ... could look at it and go, 'Wow, why isn't Microsoft doing that?" While Anthropic is innovating, Microsoft is trying to sell AI products that no one really wants. The company now has 15 million paid seats for Microsoft 365 Copilot, which brings AI tools to Office. However, with 450 million Microsoft 365 paid seats, the adoption rate is downright ane...
Duolingo shares hit their lowest price since 2023. Is the sell-off overdone? Shares of Duolingo (DUOL 8.83%) plunged 23.6% lower in January 2026, according to data from S&P Global Market Intelligence. The price drop continued a downtrend that started in 2025. The stock has backed down to prices not seen since March 2023, chiefly due to slower subscriber growth in a shaky global economy. January co...
Duolingo shares hit their lowest price since 2023. Is the sell-off overdone? Shares of Duolingo (DUOL 8.83%) plunged 23.6% lower in January 2026, according to data from S&P Global Market Intelligence. The price drop continued a downtrend that started in 2025. The stock has backed down to prices not seen since March 2023, chiefly due to slower subscriber growth in a shaky global economy. January continued the downtrend for similar reasons. The market pressure also increased when CFO Matt Skaruppa announced his departure after six years in the C-suite role. Expand NASDAQ : DUOL Duolingo Today's Change ( -8.83 %) $ -11.65 Current Price $ 120.28 Key Data Points Market Cap $6.1B Day's Range $ 119.61 - $ 129.50 52wk Range $ 119.61 - $ 544.93 Volume 5M Avg Vol 2.1M Gross Margin 71.39 % A strategic pivot meets a CFO exit Let me set the stage for January's drama. In November 2025, Duolingo CEO Luis von Ahn sketched out a slightly different business plan for the next couple of years. The company had focused on profitable monetization in recent years, but some investors were spooked that Duolingo's subscriber growth slowed down in every category. So von Ahn adjusted his management strategy to optimize subscriber growth and teaching quality a bit more. He's not giving up on revenue and profits, but making larger investments in growth-boosting ideas. Against this backdrop, Duolingo's stock price continued to slide in November and December. After the Happy New Year celebrations (Gott nytt år, Feliz Año Nuevo, Frohes Neues, and so on) the downtrend just continued. On Jan. 8, Matt Skaruppa announced his departure without much market fanfare. The CFO update was paired with updated guidance for the fourth quarter. Daily active users (DAUs) will come in just below the guidance target management provided in November, while bookings will land above the previously given guidance range. That's the news, provided amid an unpredictable macroeconomic situation that makes many consumers think...